DVAX
Price
$11.80
Change
+$0.46 (+4.06%)
Updated
Apr 19, 6:59 PM EST
12 days until earnings call
ZTS
Price
$146.45
Change
-$6.75 (-4.41%)
Updated
Apr 19, 6:59 PM EST
12 days until earnings call
Ad is loading...

Analysis and predictions DVAX vs ZTS

Header iconDVAX vs ZTS Comparison
Open Charts DVAX vs ZTSBanner chart's image
Dynavax Technologies
Price$11.80
Change+$0.46 (+4.06%)
Volume$5.52M
CapitalizationN/A
ZOETIS
Price$146.45
Change-$6.75 (-4.41%)
Volume$2.46M
CapitalizationN/A
View a ticker or compare two or three
DVAX vs ZTS Comparison Chart

Loading...

DVAXDaily Signal changed days agoGain/Loss if shorted
 
Show more...
ZTSDaily Signal changed days agoGain/Loss if shorted
 
Show more...
VS
DVAX vs. ZTS commentary
Apr 20, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is DVAX is a Hold and ZTS is a Hold.

COMPARISON
Comparison
Apr 20, 2024
Stock price -- (DVAX: $11.80 vs. ZTS: $146.50)
Brand notoriety: DVAX: Not notable vs. ZTS: Notable
Both companies represent the Pharmaceuticals: Other industry
Current volume relative to the 65-day Moving Average: DVAX: 464% vs. ZTS: 167%
Market capitalization -- DVAX: $1.62B vs. ZTS: $77.48B
DVAX [@Pharmaceuticals: Other] is valued at $1.62B. ZTS’s [@Pharmaceuticals: Other] market capitalization is $77.48B. The market cap for tickers in the [@Pharmaceuticals: Other] industry ranges from $77.48B to $0. The average market capitalization across the [@Pharmaceuticals: Other] industry is $2.8B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

DVAX’s FA Score shows that 1 FA rating(s) are green whileZTS’s FA Score has 1 green FA rating(s).

  • DVAX’s FA Score: 1 green, 4 red.
  • ZTS’s FA Score: 1 green, 4 red.
According to our system of comparison, both DVAX and ZTS are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

DVAX’s TA Score shows that 4 TA indicator(s) are bullish while ZTS’s TA Score has 4 bullish TA indicator(s).

  • DVAX’s TA Score: 4 bullish, 4 bearish.
  • ZTS’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, ZTS is a better buy in the short-term than DVAX.

Price Growth

DVAX (@Pharmaceuticals: Other) experienced а -0.34% price change this week, while ZTS (@Pharmaceuticals: Other) price change was -2.04% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was -2.92%. For the same industry, the average monthly price growth was +31.23%, and the average quarterly price growth was +18751.65%.

Reported Earning Dates

DVAX is expected to report earnings on Aug 01, 2024.

ZTS is expected to report earnings on Aug 01, 2024.

Industries' Descriptions

@Pharmaceuticals: Other (-2.92% weekly)

Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.

SUMMARIES
A.I.dvisor published
a Summary for DVAX with price predictions.
OPEN
A.I.dvisor published
a Summary for ZTS with price predictions.
OPEN
FUNDAMENTALS
Fundamentals
ZTS($77.5B) has a higher market cap than DVAX($1.62B). ZTS (32.94) and DVAX (31.63) have similar P/E ratio . DVAX YTD gains are higher at: -18.884 vs. ZTS (-22.249). ZTS has higher annual earnings (EBITDA): 3.67B vs. DVAX (9.67M). ZTS has more cash in the bank: 2.04B vs. DVAX (742M). DVAX has less debt than ZTS: DVAX (257M) vs ZTS (6.76B). ZTS has higher revenues than DVAX: ZTS (8.54B) vs DVAX (232M).
DVAXZTSDVAX / ZTS
Capitalization1.62B77.5B2%
EBITDA9.67M3.67B0%
Gain YTD-18.884-22.24985%
P/E Ratio31.6332.9496%
Revenue232M8.54B3%
Total Cash742M2.04B36%
Total Debt257M6.76B4%
FUNDAMENTALS RATINGS
DVAX vs ZTS: Fundamental Ratings
DVAX
ZTS
OUTLOOK RATING
1..100
5963
VALUATION
overvalued / fair valued / undervalued
1..100
73
Overvalued
82
Overvalued
PROFIT vs RISK RATING
1..100
6350
SMR RATING
1..100
9019
PRICE GROWTH RATING
1..100
6264
P/E GROWTH RATING
1..100
378
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

DVAX's Valuation (73) in the Biotechnology industry is in the same range as ZTS (82) in the Pharmaceuticals Generic industry. This means that DVAX’s stock grew similarly to ZTS’s over the last 12 months.

ZTS's Profit vs Risk Rating (50) in the Pharmaceuticals Generic industry is in the same range as DVAX (63) in the Biotechnology industry. This means that ZTS’s stock grew similarly to DVAX’s over the last 12 months.

ZTS's SMR Rating (19) in the Pharmaceuticals Generic industry is significantly better than the same rating for DVAX (90) in the Biotechnology industry. This means that ZTS’s stock grew significantly faster than DVAX’s over the last 12 months.

DVAX's Price Growth Rating (62) in the Biotechnology industry is in the same range as ZTS (64) in the Pharmaceuticals Generic industry. This means that DVAX’s stock grew similarly to ZTS’s over the last 12 months.

DVAX's P/E Growth Rating (3) in the Biotechnology industry is significantly better than the same rating for ZTS (78) in the Pharmaceuticals Generic industry. This means that DVAX’s stock grew significantly faster than ZTS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
DVAXZTS
RSI
ODDS (%)
Bullish Trend 2 days ago
83%
Bullish Trend 2 days ago
84%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
80%
Bullish Trend 2 days ago
58%
Momentum
ODDS (%)
Bearish Trend 2 days ago
72%
N/A
MACD
ODDS (%)
Bearish Trend 2 days ago
75%
Bearish Trend 2 days ago
59%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
79%
Bearish Trend 2 days ago
52%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
77%
Bearish Trend 2 days ago
53%
Advances
ODDS (%)
Bullish Trend 26 days ago
82%
Bullish Trend 23 days ago
60%
Declines
ODDS (%)
Bearish Trend 2 days ago
82%
Bearish Trend 5 days ago
53%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 2 days ago
68%
Aroon
ODDS (%)
Bearish Trend 2 days ago
79%
Bearish Trend 2 days ago
62%
View a ticker or compare two or three
Ad is loading...
DVAXDaily Signal changed days agoGain/Loss if shorted
 
Show more...
ZTSDaily Signal changed days agoGain/Loss if shorted
 
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
WKEY2.180.04
+1.87%
WISeKey International Holding Ltd
ULTA425.110.56
+0.13%
Ulta Beauty
JOBY4.57-0.04
-0.87%
Joby Aviation
NRC32.87-0.45
-1.35%
National Research Corp
AKYA3.85-0.06
-1.53%
Akoya BioSciences

DVAX and

Correlation & Price change

A.I.dvisor indicates that over the last year, DVAX has been loosely correlated with ACET. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if DVAX jumps, then ACET could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DVAX
1D Price
Change %
DVAX100%
-0.79%
ACET - DVAX
39%
Loosely correlated
-10.79%
SNDL - DVAX
35%
Loosely correlated
N/A
PETQ - DVAX
28%
Poorly correlated
+0.63%
AMPH - DVAX
27%
Poorly correlated
-3.50%
VTRS - DVAX
27%
Poorly correlated
+0.18%
More

ZTS and

Correlation & Price change

A.I.dvisor indicates that over the last year, ZTS has been loosely correlated with ELAN. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if ZTS jumps, then ELAN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ZTS
1D Price
Change %
ZTS100%
+1.06%
ELAN - ZTS
46%
Loosely correlated
+1.19%
HLN - ZTS
35%
Loosely correlated
+0.25%
SNDL - ZTS
33%
Loosely correlated
N/A
PETQ - ZTS
31%
Poorly correlated
+0.63%
EVO - ZTS
31%
Poorly correlated
-1.24%
More